MICROBIAL COMMUNITY AND METABOLITE IN GUT MICROBIOME OF LONG-TERM VEGETARIAN AND BIOMARKER ASSOCIATED TO HEALTH CONDITIONS

• Conditions: 1. body mass index; BMI is lower than 25. 2. Healthy (Do not have chronic diseases related to the gastrointestinal tract and Metabolic Syndrome e.g., obesity, diabetes (types 1 and 2), high blood pressure, fatty liver disease, cardiovascular disease, Crohn' s disease, Ulcerative colitis, Bacterial overgrowth syndrome, Celiac disease and Irritable Bowel Syndrome).3. People who do not have Haemophilia or Hemorrhagic disease, liver disease, heart disease, or people who must not receive medicine which affects on blood clotting such as warfarin, rivaroxaban Dabigatran, Apixaban, Edoxaban and Heparin.; Vegan health, Gut Microbiota, Metabolite

• Registration Number: TCTR20240619003
• Lead Sponsor: Faculty of Science, Chulalongkorn University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-06-19
• Last Update Posted: 19 August 2024
• Study Completion: 2025-02-28

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: Female
• Target Recruitment: 68

Inclusion Criteria

For 34 vegans
1. Vegan diet intake is at least 5 years
2. Female with age 55 years and over
3. Do not take antibiotics, probiotics, vitamin D and calcium for more than 3 months
4. Do not drink alcohol and smoke regularly.
5. body mass index; BMI is lower than 25.
6. Healthy (Do not have chronic diseases related to the gastrointestinal tract and Metabolic Syndrome e.g., obesity, diabetes (types 1 and 2), high blood pressure, fatty liver disease, cardiovascular disease, Crohn's disease, Ulcerative colitis, Bacterial overgrowth syndrome, Celiac disease and Irritable Bowel Syndrome).
7. People who do not have Haemophilia or Hemorrhagic disease, liver disease, heart disease, or people who must not receive medicine which affects on blood clotting such as warfarin, rivaroxaban Dabigatran, Apixaban, Edoxaban and Heparin.
For 34 Omnivores
1. Female with age 55 years and over
2. Do not take antibiotics, probiotics, vitamin D and calcium for more than 3 months
3. Do not drink alcohol and smoke regularly.
4. body mass index; BMI is lower than 25.
5. Healthy (Do not have chronic diseases related to the gastrointestinal tract and Metabolic Syndrome e.g., obesity, diabetes (types 1 and 2), high blood pressure, fatty liver disease, cardiovascular disease, Crohn's disease, Ulcerative colitis, Bacterial overgrowth syndrome, Celiac disease and Irritable Bowel Syndrome).
6. People who do not have Haemophilia or Hemorrhagic disease, liver disease, heart disease, or people who must not receive medicine which affects on blood clotting such as warfarin, rivaroxaban Dabigatran, Apixaban, Edoxaban and Heparin.

Exclusion Criteria

1. Absent
2. Have diarrhea or have a disease related to the gastrointestinal tract during proceeding with collecting data and samples

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Gut microbiota at 12 months after sample collection Measure in stool sample,Metabolites profile at 12 months after sample collection Measure in blood and urine,Osteoporosis risk (bone mineral density) at 3 months after sample collection DEXA scan,Information on food consumed at 12 months after sample collection Questionnaires (Physical activity, TASTE-26, Dietary recall 24 h)

Secondary Outcome Measures

Name	Time	Method
The the relationship patterns between gut microbiota and metabolites at 12 months after sample collection Bioinformatic